Szegedi et al., 2005 - Google Patents

Pentapeptides derived from Aβ1–42 protect neurons from the modulatory effect of Aβ fibrils—an in vitro and in vivo electrophysiological study

Szegedi et al., 2005

View PDF
Document ID
1191824859083477209
Author
Szegedi V
Fülöp L
Farkas T
Rozsa E
Robotka H
Kis Z
Penke Z
Horváth S
Molnar Z
Datki Z
Soós K
Toldi J
Budai D
Zarándi M
Penke B
Publication year
Publication venue
Neurobiology of disease

External Links

Snippet

Short fragments and fragment analogues of beta-amyloid 1–42 peptide (Aβ1–42) display a protective effect against Aβ-mediated neurotoxicity. After consideration of our earlier results with in vitro bioassay of synthetic Aβ-recognition peptides and toxic fibrillar amyloids, five …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides

Similar Documents

Publication Publication Date Title
Theodore et al. Intraneuronal delivery of protein kinase C pseudosubstrate leads to growth cone collapse
Curcio et al. Calpains and neuronal damage in the ischemic brain: The swiss knife in synaptic injury
Szegedi et al. Pentapeptides derived from Aβ1–42 protect neurons from the modulatory effect of Aβ fibrils—an in vitro and in vivo electrophysiological study
KR101491860B1 (en) Mu-conotoxin peptides and use thereof as a local anesthetic
AU2018260893B2 (en) Neurodegenerative disorders
Origlia et al. Aβ-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: The role of RAGE
JP6483858B2 (en) Scorpion poison heat-resistant synthetic peptide
US8546086B2 (en) Use of neuregulin-β as an indicator and/or target
Choi et al. Naringin enhances long-term potentiation and recovers learning and memory deficits of amyloid-beta induced Alzheimer’s disease-like behavioral rat model
Cifelli et al. Changes in the sensitivity of GABAA current rundown to drug treatments in a model of temporal lobe epilepsy
Zhou et al. Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43
Smirnova et al. Neuroprotective signal transduction in model motor neurons exposed to thrombin: G‐protein modulation effects on neurite outgrowth, Ca2+ mobilization, and apoptosis
Kiris et al. Evaluation of the therapeutic effect of lycoramine on Alzheimer’s disease in mouse model
Ogara et al. CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive functions
Szegedi et al. Endomorphin‐2, an endogenous tetrapeptide, protects against Aβ1–42 in vitro and in vivo
Larsen et al. Effect of isoflurane on release and uptake of gamma-aminobutyric acid from rat cortical synaptosomes
Mackiewicz et al. Targeting CaN/NFAT in Alzheimer’s brain degeneration
Zhang et al. Protein kinase C mediates amyloid β-protein fragment 31–35-induced suppression of hippocampal late-phase long-term potentiation in vivo
Zhang et al. Influence of oxodiperoxovanadate complexes on prion neuropeptide fibril formation
US8088892B2 (en) Inhibitors of proteins from the Rho-GEF family
Ham et al. Cell-based screen using amyloid mimic β23 expression identifies peucedanocoumarin III as a novel inhibitor of α-synuclein and Huntingtin aggregates
Zhang et al. S-Nitrosylation of CRTC1 in Alzheimer's disease impairs CREB-dependent gene expression induced by neuronal activity
Torkamani-Dordshaikh et al. Exploring the therapeutic potential: Apelin-13’s neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington’s disease
WO1999019477A1 (en) Cadherin derived growth factor and the application thereof
Lyubashina et al. NO-Dependent mechanisms of amygdalofugal modulation of hypothalamic autonomic neurons